Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Targeting GLP-1 receptor trafficking to improve agonist efficacy
Ben Jones, Teresa Buenaventura, Nisha Kanda, et al.
Nature Communications (2018) Vol. 9, Iss. 1
Open Access | Times Cited: 206

Showing 1-25 of 206 citing articles:

Glucagon-like peptide 1 (GLP-1)
Timo D. Müller, Brian Finan, Stephen R. Bloom, et al.
Molecular Metabolism (2019) Vol. 30, pp. 72-130
Open Access | Times Cited: 1306
Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
Francis S. Willard, Jonathan D. Douros, M Gabe, et al.
JCI Insight (2020) Vol. 5, Iss. 17
Open Access | Times Cited: 301
GIP as a Therapeutic Target in Diabetes and Obesity: Insight From Incretin Co-agonists
Jens J. Holst, Mette M. Rosenkilde
The Journal of Clinical Endocrinology & Metabolism (2020) Vol. 105, Iss. 8, pp. e2710-e2716
Open Access | Times Cited: 146
A Small-Molecule Oral Agonist of the Human Glucagon-like Peptide-1 Receptor
David A. Griffith, David J. Edmonds, Jean‐Philippe Fortin, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 12, pp. 8208-8226
Open Access | Times Cited: 91
GLP-1 and GIP receptor signaling in beta cells – A review of receptor interactions and co-stimulation
Ashok Mayendraraj, Mette M. Rosenkilde, Lærke S. Gasbjerg
Peptides (2022) Vol. 151, pp. 170749-170749
Open Access | Times Cited: 82
Incretin hormones and type 2 diabetes
Michael A. Nauck, Timo D. Müller
Diabetologia (2023) Vol. 66, Iss. 10, pp. 1780-1795
Open Access | Times Cited: 78
GWAS of random glucose in 476,326 individuals provide insights into diabetes pathophysiology, complications and treatment stratification
Vasiliki Lagou, Longda Jiang, Anna Ulrich, et al.
Nature Genetics (2023) Vol. 55, Iss. 9, pp. 1448-1461
Open Access | Times Cited: 48
Arrestin‐independent internalization of the GLP‐1 receptor is facilitated by a GRK, clathrin, and caveolae‐dependent mechanism
Ee Von Moo, Thor C. Møller, Flemming Brandt Sørensen, et al.
FEBS Journal (2025)
Open Access | Times Cited: 2
Glucose-dependent insulinotropic polypeptide (GIP)
Timo D. Müller, Alice E. Adriaenssens, Bo Ahrén, et al.
Molecular Metabolism (2025) Vol. 95, pp. 102118-102118
Open Access | Times Cited: 2
Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist
Takahiro Kawai, Bingfa Sun, Hitoshi Yoshino, et al.
Proceedings of the National Academy of Sciences (2020) Vol. 117, Iss. 47, pp. 29959-29967
Open Access | Times Cited: 123
Agonist-induced membrane nanodomain clustering drives GLP-1 receptor responses in pancreatic beta cells
Teresa Buenaventura, Stavroula Bitsi, William E. Laughlin, et al.
PLoS Biology (2019) Vol. 17, Iss. 8, pp. e3000097-e3000097
Open Access | Times Cited: 90
β-Arrestin Based Receptor Signaling Paradigms: Potential Therapeutic Targets for Complex Age-Related Disorders
Jaana van Gastel, Jhana O. Hendrickx, Hanne Leysen, et al.
Frontiers in Pharmacology (2018) Vol. 9
Open Access | Times Cited: 86
Arrestin-Dependent and -Independent Internalization of G Protein–Coupled Receptors: Methods, Mechanisms, and Implications on Cell Signaling
Ee Von Moo, Jeffrey R. van Senten, Hans Bräuner‐Osborne, et al.
Molecular Pharmacology (2021) Vol. 99, Iss. 4, pp. 242-255
Open Access | Times Cited: 73
The Interplay of Glucagon-Like Peptide-1 Receptor Trafficking and Signalling in Pancreatic Beta Cells
Amaara Marzook, Alejandra Tomás, Ben Jones
Frontiers in Endocrinology (2021) Vol. 12
Open Access | Times Cited: 70
Structural determinants of dual incretin receptor agonism by tirzepatide
Bingfa Sun, Francis S. Willard, Dan Feng, et al.
Proceedings of the National Academy of Sciences (2022) Vol. 119, Iss. 13
Open Access | Times Cited: 68
Fibronectin type III domain‐containing 5 improves aging‐related cardiac dysfunction in mice
Can Hu, Xin Zhang, Min Hu, et al.
Aging Cell (2022) Vol. 21, Iss. 3
Open Access | Times Cited: 67
Spatiotemporal GLP-1 and GIP receptor signaling and trafficking/recycling dynamics induced by selected receptor mono- and dual-agonists
Aaron Novikoff, Shannon O’Brien, Miriam Bernecker, et al.
Molecular Metabolism (2021) Vol. 49, pp. 101181-101181
Open Access | Times Cited: 61
Dynamics of GLP-1R peptide agonist engagement are correlated with kinetics of G protein activation
Giuseppe Deganutti, Yi-Lynn Liang, Xin Zhang, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 58
Pharmacogenomics of GLP-1 receptor agonists: a genome-wide analysis of observational data and large randomised controlled trials
Adem Y. Dawed, Andrea Mari, Andrew Brown, et al.
The Lancet Diabetes & Endocrinology (2022) Vol. 11, Iss. 1, pp. 33-41
Open Access | Times Cited: 55
The molecular pharmacology of glucagon agonists in diabetes and obesity
Aaron Novikoff, Timo D. Müller
Peptides (2023) Vol. 165, pp. 171003-171003
Open Access | Times Cited: 40
Enhanced Endosomal Signaling and Desensitization of GLP-1R vs GIPR in Pancreatic Beta Cells
Yusman Manchanda, Stavroula Bitsi, Shiqian Chen, et al.
Endocrinology (2023) Vol. 164, Iss. 5
Open Access | Times Cited: 28
Safety and efficacy of the new, oral, small-molecule, GLP-1 receptor agonists orforglipron and danuglipron for the treatment of type 2 diabetes and obesity: systematic review and meta-analysis of randomized controlled trials
Paschalis Karakasis, Dimitrios Patoulias, Konstantinos Pamporis, et al.
Metabolism (2023) Vol. 149, pp. 155710-155710
Closed Access | Times Cited: 27
GLP-1R signaling neighborhoods associate with the susceptibility to adverse drug reactions of incretin mimetics
Shane C. Wright, Aikaterini Motso, Stefania Koutsilieri, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 25
The importance of glucose‐dependent insulinotropic polypeptide receptor activation for the effects of tirzepatide
Lærke S. Gasbjerg, Mette M. Rosenkilde, Juris J. Meier, et al.
Diabetes Obesity and Metabolism (2023) Vol. 25, Iss. 11, pp. 3079-3092
Closed Access | Times Cited: 24
Human GLP1R variants affecting GLP1R cell surface expression are associated with impaired glucose control and increased adiposity
Wenwen Gao, Lei Liu, Eunna Huh, et al.
Nature Metabolism (2023) Vol. 5, Iss. 10, pp. 1673-1684
Open Access | Times Cited: 23
Page 1 - Next Page

Scroll to top